Susan Collins actually said...

"What we found was a system of getting insulin from the manufacturer to the customer that was rife with perverse incentives, convoluted and opaque."

"I think we have a very strange system here because--to say the least, because most of us would think that the rebate, the discount that is negotiated by the PBMs, would largely benefit the consumer at..."

"In 2018, I chaired a hearing of the Senate Aging Committee on why the costs of insulin was so high."

"In my judgment, there is no investment that pays greater dividends to American families than our investment in biomedical research."